Indaptus Therapeutics (INDP) said Wednesday it received clinical trial authorization from Health Canada for its Decoy20 drug candidate.
The approval allows expansion of the company's ongoing US phase 1 study, INDP-D101, in patients with locally advanced or metastatic solid tumors to Canadian sites, according to Indaptus.
The company said it will enroll patients in Canada under the current protocol of weekly dosing of Decoy20. Indaptus plans to amend the Health Canada submission to include its upcoming Decoy20 and BeiGene's tislelizumab combination trial.
Shares of the company were down 1.3% in recent trading.
Price: 0.89, Change: -0.01, Percent Change: -1.33
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。